Adult Patients With Type 2 DiabetesPhase 3NCT06871761
A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
A Phase 3 study testing HR17031 injection and insulin glargine in people with Adult Patients With Type 2 Diabetes, run by Jiangsu HengRui Medicine Co., Ltd. at 1 site in China.
Trial summary
To compare the efficacy and safety of HR17031 injection and insulin glargine, including the changes of efficacy indicators such as HbA1c, fasting blood glucose, body weight and safety indicators such as adverse events and hypoglycemic events. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Adult Patients With Type 2 Diabetes
- What is being tested?
- HR17031 injection and insulin glargine
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 393 participants
- Where
- 1 siteChina
- Study dates
- 8 May 2024to 13 May 2025
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female, aged 18-75 years at the time of signing the informed consent (both ends included)
- Body Mass index (BMI) of 20.0-40.0 kg/m2 (both ends included)
- Diagnosed with type 2 diabetes for at least 90 days prior to screening
- Tested by local laboratory, HbA1c is 7.5%-10.5% (including both ends)
- Before screening, the daily basal insulin dose had been stabilized at 20-40U/ day (including both ends) for at least 60 days
- Stable treatment with metformin alone or in combination with another OAD for ≥60 days prior to screening. Metformin dose ≥1500 mg/ day or maximum tolerated dose.
- Ability and willingness to comply with protocol requirements, including self-monitoring of blood glucose, recording subject diary, and using pre-filled injection pen.
Who cannot join
- Known or suspected allergy to the investigational drug product or its components or excipients;
- Systemic glucocorticoid use within 3 months prior to screening
- Use of weight loss drugs within 3 months prior to screening
- Insulin therapy other than basal insulin was used within 3 months prior to screening
- Cardiovascular disease, defined as congestive heart failure (NYHA III-IV), unstable angina pectoris, stroke (except lacunar infarction without symptoms), myocardial infarction, coronary revascularization within 6 months prior to screening; And/or coronary, carotid, or peripheral arterial revascularization is planned at screening
- (with or without treatment) uncontrolled severe hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg)
Show all 12Show fewer
- Proliferative retinopathy or macular degeneration requiring acute treatment, painful diabetic neuropathy, diabetic foot ulcers, intermittent claudication at screening;
- Patients diagnosed with mental disorders; Mentally incapacitated or speech impediment, unable to fully understand the trial protocol or unwilling to collaborate;
- Known or suspected abuse of alcohol or narcotics;
- Previous history of pancreatitis (acute or chronic)
- During pregnancy or lactation;fertile women (WOCBP) or men who have fertility plan or unwilling to use appropriate contraceptive methods from the signing of the informed consent to 3 months after last use of the investigational drug product;
- Any condition, determined by the investigator, interfere with the efficacy or safety results of the trial.
Trial locations and contacts
1 site in 1 country.
China1 site
Shanghai Zhu Xianyi Memorial Hospital, Tianjin Medical University
Tianjin, Tianjin Municipality, 300400
About this study
Official title: A Randomized, Open-label, Parallel, Treat to Target Study Comparing the Efficacy and Safety of HR17031 Injection With Insulin Glargine in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin, Metformin in Combination With or Without One Other Oral Antidiabetic Drug (OAD)
To compare the efficacy and safety of HR17031 injection and insulin glargine, including the changes of efficacy indicators such as HbA1c, fasting blood glucose, body weight and safety indicators such as adverse events and hypoglycemic events.
- Conditions
- Adult Patients With Type 2 Diabetes
- Being tested
- HR17031 injection, insulin glargine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HR17031 injectionDrug
HR17031 injection
insulin glargineDrug
insulin glargine
| Study group | Role | What they receive |
|---|---|---|
| Treatment group A: HR17031 injection | Experimental | Not described Receives: Drug: HR17031 injection |
| Treatment group B: insulin glargine | Active comparator | Not described Receives: Drug: insulin glargine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in HbA1c from baseline to week 26
Measured: from baseline to week 26
Secondary outcomes (8)
Proportion of subjects achieved HbA1c<7.0% at week 26
Measured: at week 26
Change in body weight from baseline to week 26
Measured: from baseline to week 26
Proportion of subjects achieved HbA1c<7.0% and no weight gain at week 26
Measured: at week 26
Daily Insulin dose at week 26
Measured: at week 26
The proportion of subjects achieved HbA1c≤6.5% at week 26
Measured: at week 26
Changes in FPG from baseline to week 26
Measured: from baseline to week 26
Hypoglycemic event from screening to week 27
Measured: from screening to week 27
Adverse events from screening to week 27
Measured: from screening to week 27
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2025
- Study start8 May 2024
- Primary completion13 May 2025
- Study completion13 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adult Patients With Type 2 DiabetesStudies of the same condition, open and under way.
- More trials run by Jiangsu HengRui Medicine Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 393 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06871761
- Sponsor's protocol ID
- HR17031-302
- Status last verified
- Feb 2025
- First submitted
- 26 Feb 2025
- Last updated
- 13 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Open-label, Parallel, Treat to Target Study Comparing the Efficacy and Safety of HR17031 Injection With Insulin Glargine in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin, Metformin in Combination With or Without One Other Oral Antidiabetic Drug (OAD)
- ClinicalTrials.gov ID
- NCT06871761
- Acronym / sponsor ID
- HR17031-302
- Conditions
- Adult Patients With Type 2 Diabetes
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 393 participants (actual)
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 8 May 2024 (actual)
- Primary completion
- 13 May 2025 (actual)
- Study completion
- 13 May 2025 (actual)
- First posted
- 12 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To compare the efficacy and safety of HR17031 injection and insulin glargine, including the changes of efficacy indicators such as HbA1c, fasting blood glucose, body weight and safety indicators such as adverse events and hypoglycemic events.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treatment group A: HR17031 injection | Experimental | Drug: HR17031 injection |
| Treatment group B: insulin glargine | Active comparator | Drug: insulin glargine |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Male or female, aged 18-75 years at the time of signing the informed consent (both ends included)
- Body Mass index (BMI) of 20.0-40.0 kg/m2 (both ends included)
- Diagnosed with type 2 diabetes for at least 90 days prior to screening
- Tested by local laboratory, HbA1c is 7.5%-10.5% (including both ends)
- Before screening, the daily basal insulin dose had been stabilized at 20-40U/ day (including both ends) for at least 60 days
Key exclusion criteria (12 listed)
- Known or suspected allergy to the investigational drug product or its components or excipients;
- Systemic glucocorticoid use within 3 months prior to screening
- Use of weight loss drugs within 3 months prior to screening
- Insulin therapy other than basal insulin was used within 3 months prior to screening
- Cardiovascular disease, defined as congestive heart failure (NYHA III-IV), unstable angina pectoris, stroke (except lacunar infarction without symptoms), myocardial infarction, coronary revascularization within 6 months prior to screening; And/or coronary, carotid, or peripheral arterial revascularization is planned at screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HR17031 injectionHR17031 injection | Drug | Treatment group A: HR17031 injection |
| insulin glargineinsulin glargine | Drug | Treatment group B: insulin glargine |
Primary outcome
Changes in HbA1c from baseline to week 26
Time frame: from baseline to week 26
8 secondary outcomes
Proportion of subjects achieved HbA1c<7.0% at week 26
Time frame: at week 26
Change in body weight from baseline to week 26
Time frame: from baseline to week 26
Proportion of subjects achieved HbA1c<7.0% and no weight gain at week 26
Time frame: at week 26
Daily Insulin dose at week 26
Time frame: at week 26
The proportion of subjects achieved HbA1c≤6.5% at week 26
Time frame: at week 26
Changes in FPG from baseline to week 26
Time frame: from baseline to week 26
Hypoglycemic event from screening to week 27
Time frame: from screening to week 27
Adverse events from screening to week 27
Time frame: from screening to week 27
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Adult Patients With Type 2 Diabetes
RecruitingPhase 3
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
A Nurse-Led Personalized Self-Management Counseling Intervention to Improve Medication Adherence and Glycemic Control in Adults With Type 2 Diabetes: A Randomized Controlled Trial
Medication Adherence, Glycemic Control for Diabetes Mellitus
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
Not yet recruitingPhase 2
Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Poor Glycemic Control Despite Lifestyle Intervention
Diabetes Mellitus, Type 2
Not yet recruiting
A Novel Miniature Equine-Assisted Diabetes Education Program for Youth: Evaluating the Diabetes Equine Empowerment Program (DEEP).
Diabetes (Insulin-requiring, Type 1 or Type 2), Pediatric Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing HR17031 injection and insulin glargine in people with Adult Patients With Type 2 Diabetes, run by Jiangsu HengRui Medicine Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in HbA1c from baseline to week 26 (time frame: from baseline to week 26). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.